Browsing Centre for Biochemical Pharmacology by Author "Gil, EG"
Now showing items 1-5 of 5
-
Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use
Jackson, DJ; Burhan, H; Menzies-Gow, A; Pfeffer, P; Nanzer, A; Gil, EG; Morris, T; Tran, TN; Hirsch, I; Dube, S (2022) -
Clinical Effectiveness of Benralizumab Is Independent of Baseline FeNO in Severe Eosinophilic Asthma: A Retrospective Real-World Observation Study in Five UK Severe Asthma Centers
Jackson, DJ; Burhan, H; Menzies-Gow, A; Pfeffer, PE; Nanzer, A; Gil, EG; Morris, T; Tran, TN; Hirsch, I; Dube, S (2021-05-01) -
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
Pfeffer, PE; Ali, N; Murray, R; Ulrik., C; Tran, TN; Maspero, J; Peters, M; Christoff, GC; Sadatsafavi, M; Torres-Duque, CA (2023) -
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both
Price, D; pfeffer, P; Ali, N; Murray, R; Ulrik, C; Tran, T; Maspero, J; Peters, M; Christoff, G; Sadatsafavi, M (2022) -
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry.
Chen, W; Tran, TN; Sadatsafavi, M; Murray, R; Wong, NCB; Ali, N; Ariti, C; Bulathsinhala, L; Gil, EG; FitzGerald, JM (2023-09)BACKGROUND: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. OBJECTIVE: To examine the ...